Genmab


Strong Q3; guidance upgrade driven by FX

08/11/19 -"Darzalex continued to gain market share in Q3, while Arzerra was once again a disappointment. Given the favourable development in FX, the revenue guidance was upgraded by DKK300m and, as operating ..."

Pages
51
Language
English
Published on
08/11/19
You may also be interested by these reports :
26/08/26
We upgrade Novonesis to ADD from Reduce. The Q2 26 results marked a clear inflection point: broad-based organic growth (+9%, well ahead of consensus) ...

24/08/26
Q2 profitability beat expectations; however, the top line lagged consensus. The quarterly growth was driven by strong performance in LatAm, Animal ...

21/08/26
The H1 profitability surpassed consensus, though sales matched expectations. The Branded segment was the sole driver of sales growth in H1, though ...

21/08/26
Siegfried delivered a strong set of results in 1H26. Net sales grew by +2.2% YoY (+4.8% in LC), largely supported by the additional revenues ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO